Collagenase Clostridium Histolyticum-aaes

Class: Enzymes
Brands: Qwo

Medically reviewed by Drugs.com on Feb 8, 2021. Written by ASHP.

Introduction

Collagenase clostridium histolyticum-aaes is a combination of bacterial collagenase enzymes.

Uses for Collagenase Clostridium Histolyticum-aaes

Collagenase clostridium histolyticum-aaes has the following uses:

Collagenase clostridium histolyticum-aaes is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

Collagenase Clostridium Histolyticum-aaes Dosage and Administration

General

Collagenase clostridium histolyticum-aaes is available in the following dosage form(s) and strength(s):

For injection: 0.92 mg or 1.84 mg as a lyophilized powder in single-dose vials.

Dosage

It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Adults

Dosage and Administration

• A treatment area is defined as a single buttock receiving up to 12 injections, 0.3 mL each (up to a total of 3.6 mL), of collagenase clostridium histolyticum-aaes.

• A treatment visit may consist of up to 2 treatment areas. Treatment visits should be repeated every 21 days for 3 treatment visits.

• Reconstitute collagenase clostridium histolyticum-aaes lyophilized powder with the supplied diluent prior to use.

• Inject 0.84 mg of collagenase clostridium histolyticum-aaes per treatment area as 12 subcutaneous injections (0.3-mL injection administered as three 0.1-mL aliquots per injection).

Cautions for Collagenase Clostridium Histolyticum-aaes

Contraindications

• History of hypersensitivity to any collagenase or to any of the components in the formulation.

• Infection at the injection site.

Warnings/Precautions

Hypersensitivity Reactions

Serious hypersensitivity reactions including anaphylaxis have been reported with the use of collagenase clostridium histolyticum. If such a reaction occurs, further injection of collagenase clostridium histolyticum-aaes should be discontinued and appropriate medical therapy immediately instituted.

Injection Site Bruising

In clinical trials, 84% of subjects treated with collagenase clostridium histolyticum-aaes experienced injection site bruising. Subjects with coagulation disorders or using anticoagulant or antiplatelet medications (except those taking ≤150 mg aspirin daily) were excluded from participating in Trials 1 and 2.